Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day
Xilio Therapeutics, Inc. (Nasdaq: XLO) will host a virtual fireside chat at the Guggenheim 4th Annual Oncology Day on February 10, 2022, at 8:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xilio Therapeutics, Inc. (Nasdaq: XLO) will host a virtual fireside chat at the Guggenheim 4th Annual Oncology Day on February 10, 2022, at 8:30 a.m. ET. The event will feature CEO René Russo and CMO Marty Huber discussing the company’s tumor-selective immuno-oncology therapies. A live webcast will be accessible via Xilio’s website, and a replay will be available for 30 days post-event. Xilio is dedicated to developing innovative cancer treatments utilizing its proprietary GPS platform, focusing on tumor-localized biologics aimed at enhancing anti-tumor activity.
Details
News Market Reaction – XLO
The recorded move for XLO in the trading session of this news was -3.20%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm. D., president and chief executive officer, and Marty Huber, M.D., president of research and development and chief medical officer of Xilio Therapeutics, will participate in a virtual fireside chat during the Guggenheim 4th Annual Oncology Day on Thursday, February 10, 2022, at 8:30 a.m. ET.
A live webcast will be available in the Investors and Media section of the Xilio Therapeutics’ website at https://ir.xiliotx.com. A replay of the webcast will be archived on Xilio Therapeutics’ website for 30 days following the presentation.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics, that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX202, a tumor-selective IL-2; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15. For more information, please visit www.xiliotx.com.
For Investor Inquiries:
Chelcie Lister, THRUST Strategic Communications
chelcie@thrustsc.com
For Media Inquiries:
Dan Budwick
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.